Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Bayer (BAYZF) (BAYRY) says elinzanetant, its experimental therapy for hot flashes, reached the main goals in a late-stage ...

Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Both cognitive-behavioral therapy and clinical hypnosis are among the most effective options not involving medication.

I did not finish that yoga class. Instead, I rolled up my mat and fled the studio for the air-conditioned bathroom where I ...

This article reviews the published literature on the use of venlafaxine, fluoxetine, and paroxetine for the treatment of hot flashes.

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...

(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating the ...

The menopausal transition is an opportunity for women to cross a psychological threshold into the second half of life, but ...